NEUMORA THERAPEUTICS, INC. Operating Expenses
NEUMORA THERAPEUTICS, INC. (NMRA) reported Operating Expenses of $42.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $42.19M, a 21.93% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $52.86M, a 25.48% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $58.48M, a 7.06% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $57.70M, a 24.72% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. operating expenses for fiscal 2025 was $241.16M, a 8.47% decline from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. operating expenses for fiscal 2024 was $263.46M, a 4.51% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. operating expenses for fiscal 2023 was $252.10M, a 85.54% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. operating expenses for fiscal 2022 was $135.87M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.19M 10-Q · filed 2026-08-14 | $95.05M 10-Q · filed 2026-08-14 | $153.53M derived: sum of 3 quarters · filed 2026-08-14 | $211.23M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $52.86M 10-Q · filed 2026-05-07 | $111.34M derived: sum of 2 quarters · filed 2026-05-07 | $169.04M derived: sum of 3 quarters · filed 2026-05-07 | $223.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $58.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $116.18M derived: sum of 2 quarters · filed 2026-03-30 | $170.22M derived: sum of 3 quarters · filed 2026-08-14 | $241.16M 10-K · filed 2026-03-30 |
| 2025-09-30 | $57.70M 10-Q · filed 2025-11-06 | $111.74M derived: sum of 2 quarters · filed 2026-08-14 | $182.68M 10-Q · filed 2025-11-06 | $245.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $54.04M 10-Q · filed 2026-08-14 | $124.98M 10-Q · filed 2026-08-14 | $187.90M derived: sum of 3 quarters · filed 2026-08-14 | $264.54M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $70.94M 10-Q · filed 2026-05-07 | $133.86M derived: sum of 2 quarters · filed 2026-05-07 | $210.50M derived: sum of 3 quarters · filed 2026-05-07 | $274.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $62.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $139.57M derived: sum of 2 quarters · filed 2026-03-30 | $203.39M derived: sum of 3 quarters · filed 2026-03-30 | $263.46M 10-K · filed 2026-03-30 |
| 2024-09-30 | $76.65M 10-Q · filed 2025-11-06 | $140.47M derived: sum of 2 quarters · filed 2025-11-06 | $200.54M 10-Q · filed 2025-11-06 | $314.55M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $63.82M 10-Q · filed 2025-08-06 | $123.90M 10-Q · filed 2025-08-06 | $237.90M derived: sum of 3 quarters · filed 2025-08-06 | $294.76M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $60.07M 10-Q · filed 2025-05-12 | $174.08M derived: sum of 2 quarters · filed 2025-05-12 | $230.94M derived: sum of 3 quarters · filed 2025-05-12 | $273.00M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $114.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $170.87M derived: sum of 2 quarters · filed 2025-03-03 | $212.93M derived: sum of 3 quarters · filed 2025-03-03 | $252.10M 10-K · filed 2025-03-03 |
| 2023-09-30 | $56.86M 10-Q · filed 2024-11-12 | $98.93M derived: sum of 2 quarters · filed 2024-11-12 | $138.09M 10-Q · filed 2024-11-12 | $168.81M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $42.06M 10-Q · filed 2024-08-06 | $81.23M 10-Q · filed 2024-08-06 | $111.95M derived: sum of 3 quarters · filed 2025-03-03 | $142.55M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $39.17M 10-Q · filed 2024-05-07 | $69.89M derived: sum of 2 quarters · filed 2025-03-03 | $100.49M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $30.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $61.32M derived: sum of 2 quarters · filed 2025-03-03 | $135.87M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $30.60M 10-Q · filed 2023-11-01 | $105.15M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |